Cedrus LLC Akebia Therapeutics, Inc. Transaction History
Cedrus LLC
- $270 Billion
- Q3 2024
A detailed history of Cedrus LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Cedrus LLC holds 13,700 shares of AKBA stock, worth $26,030. This represents 0.01% of its overall portfolio holdings.
Number of Shares
13,700
Previous 13,700
-0.0%
Holding current value
$26,030
Previous $14 Million
29.41%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding AKBA
# of Institutions
115Shares Held
53.6MCall Options Held
540KPut Options Held
236K-
Black Rock Inc. New York, NY11.6MShares$22.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$19.1 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$10.9 Million13.23% of portfolio
-
Geode Capital Management, LLC Boston, MA4.75MShares$9.03 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.72MShares$7.06 Million0.01% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $349M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...